About Mustang Bio, Inc. (MBIO)
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
MBIO Key Statistics
| Current Price | $0.90 | Market Cap | $7 million |
|---|---|---|---|
| Daily Change | -5.58% | Volume | 32K |
| 52-Week High | $7.00 | 52-Week Low | $0.53 |
| Sector | Healthcare | Industry | Biotechnology |
MBIO Price Performance
Mustang Bio, Inc. stock has returned -1.04% over the past day, -7.77% over the past week, +4.40% over the past month, and -12.84% over the past three months. The stock trades between a 52-week low of $0.53 and a high of $7.00.
MBIO Financial Fundamentals
Mustang Bio, Inc. reports a return on equity (ROE) of -418.83%. Current ratio stands at 2.05.